Pharma CMO: Current Market Landscape and Future Opportunities

 The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the pharmaceutical contract manufacturing (Pharma CMO) market has grown into a prominent and promising segment of the overall pharmaceutical industry. In fact, post 2000, more than 150 new Pharma CMO players have been established, offering cost-efficient solutions to several stakeholders in the industry.

Discussions with several industry stakeholders not only confirm the present importance of pharma CMO but also highlight the value likely to be created by them in the long term.

The contract services market landscape, featuring the presence of over 500 companies, is highly fragmented; a number of players have both API and FDF manufacturing capability

As per Roots Analysis, over 60% of the pharmaceutical contract manufacturers are engaged in commercial production and method process / analytical development

Several large-sized pharma CMO players offer services across all scales of operation; most popular packaging formats include tablets / capsules / blisters and vials / cartridges

Over 70% of the pharmaceutical contract manufacturers uses tablet / capsule / blister packaging. Majority of the manufacturers are large sized.

Interestingly, despite the stringent regulatory standards, a significant proportion of pharma CMO players have procured operational approvals and certifications from the USFDA.

The current installed contract manufacturing capacity is over 100 million liters; this capacity is spread across different regions worldwide.

Driven by an increasing global demand for small molecule drugs, pharmaceutical contract manufacturing market is currently a multi-billion dollar and steadily growing industry.

Within APIs, generic drugs will continue to represent the major focus; in the case of FDFs, the future growth is expected to be driven by injectables.

A closer look at the market landscape reveals a well distributed opportunity in terms of various primary packaging forms, scale of operations and size of manufacturers

The pharmaceutical contract manufacturing market is  fragmented across various segments including packaging form, scale of operation, company size and geography. By 2028, Table / capsule / blister packaging is likely to capture the largest market share.

To learn more, please click Pharma CMO market. For any queries / suggestions, please do not hesitate to contact us at You can also download the SAMPLE REPORT on Pharma CMO by Roots Analysis.

Our Social Media Platform